Publication:
The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction.

dc.contributor.authorQuintanal-Villalonga, Álvaro
dc.contributor.authorOjeda-Márquez, Laura
dc.contributor.authorMarrugal, Ángela
dc.contributor.authorYagüe, Patricia
dc.contributor.authorPonce-Aix, Santiago
dc.contributor.authorSalinas, Ana
dc.contributor.authorCarnero, Amancio
dc.contributor.authorFerrer, Irene
dc.contributor.authorMolina-Pinelo, Sonia
dc.contributor.authorPaz-Ares, Luis
dc.date.accessioned2023-01-25T10:03:23Z
dc.date.available2023-01-25T10:03:23Z
dc.date.issued2018-02-05
dc.description.abstractThe FGFR4-388Arg variant has been related to poor prognosis in several types of cancer, including lung cancer. The mechanism underlying this association has not been addressed in detail in patients with this pathology. Here, we report that this FGFR4 variant induces MAPK and STAT3 activation and causes pro-oncogenic effects in NSCLC in vitro and in vivo. This variant induces the expression of EMT-related genes, such as N-cadherin, vimentin, Snail1 and Twist1. Indeed, the induction of N-cadherin protein expression by this variant is essential for its pro-tumorigenic role. The presence of the FGFR4-388Arg variant correlates with higher N-cadherin expression levels in clinical NSCLC samples and with poorer outcome in patients with FGFR expression. These results support the prognostic role of this FGFR variant in lung cancer and show that these effects may be mediated by the induction of N-cadherin expression and an EMT phenotype.
dc.identifier.doi10.1038/s41598-018-20570-3
dc.identifier.essn2045-2322
dc.identifier.pmcPMC5799167
dc.identifier.pmid29402970
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799167/pdf
dc.identifier.unpaywallURLhttps://www.nature.com/articles/s41598-018-20570-3.pdf
dc.identifier.urihttp://hdl.handle.net/10668/12085
dc.issue.number1
dc.journal.titleScientific reports
dc.journal.titleabbreviationSci Rep
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number2394
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshAnimals
dc.subject.meshAntigens, CD
dc.subject.meshCadherins
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshCell Line, Tumor
dc.subject.meshDisease Progression
dc.subject.meshEpithelial-Mesenchymal Transition
dc.subject.meshFemale
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshHeterografts
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMice
dc.subject.meshMice, Nude
dc.subject.meshMitogen-Activated Protein Kinases
dc.subject.meshMutation
dc.subject.meshNuclear Proteins
dc.subject.meshPrognosis
dc.subject.meshReceptor, Fibroblast Growth Factor, Type 4
dc.subject.meshSTAT3 Transcription Factor
dc.subject.meshSnail Family Transcription Factors
dc.subject.meshSurvival Analysis
dc.subject.meshTwist-Related Protein 1
dc.subject.meshVimentin
dc.titleThe FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number8
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC5799167.pdf
Size:
2.13 MB
Format:
Adobe Portable Document Format